Erythropoietins (Epostim®) during chemoradiotherapy for malignancies in anemic patients

V. A. Titova; Титова В. А.; Yu. M. Kreynina; Крейнина Ю. М.; A. N. Shipilova; Шипилова А. Н.; L. N. Shevchenko; Шевченко Л. Н.; V. Yu. Petrovsky; Петровский В. Ю.; I. V. Ose; Осе И. В.; T. F. Skobeleva; Скобелева Т. Ф.; A. V. Akimov; Акимов А. В.; A. L. Badmayev; Бадмаев А. Л.

doi:10.17650/1994-4098-2010-0-3-45-49

Erythropoietins (Epostim®) during chemoradiotherapy for malignancies in anemic patients

Authors: Titova V.A.¹, Kreynina Y.M.¹, Shipilova A.N.¹, Shevchenko L.N.¹, Petrovsky V.Y.¹, Ose I.V.², Skobeleva T.F.², Akimov A.V.², Badmayev A.L.²
Affiliations:
1. Russian Radiology Research Center, Ministry of Health and Social Development
2. OOO “Pharmapark”, Moscow
Issue: No 3 (2010)
Pages: 45-49
Section: PHARMACOTHERAPY
Published: 28.08.2010
URL: https://ojrs.abvpress.ru/ojrs/article/view/249
DOI: https://doi.org/10.17650/1994-4098-2010-0-3-45-49
ID: 249

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Anemia in female patients with solid neoplasms is corrected to normalize hemoglobin levels, to increase quality of life, and to improve antitumor therapy tolerance. The clinical application of recombinant human erythropoietin preparations has become an important treat- ment step that permits multiple hemotransfusions to be avoided. Epostim is effective and safe in increasing hemoglobin and packed cell volume and in overcoming the additive toxicity of chemo- and radiotherapy.